Radiopharm Theranostics Ltd (RADX) stock

RADXNasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as RDPTF

Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Sep 30, 2026Score 6/30

$0.76−0.03 (-3.80%)

Close on Nov 13, 2026Market cap $8.98MP/E –Yield –

Radiopharm Theranostics total assets

Total assets on the balance sheet at the end of each period.

Radiopharm Theranostics's total assets was $60.13M at Jun 30, 2026. For fiscal 2026 it was $60.13M, down 30.5% from the year before.

Period	Period end	Value	Change
FY2026	Jun 30, 2026	$60.13M	-30.5%
FY2025	Jun 30, 2025	$86.48M	+20.1%
FY2024	Jun 30, 2024	$72.04M	–

Change is against the same quarter a year earlier.

Periods

Period	Period end	Value	Change
Q4 FY2026CQ2 2026	Jun 30, 2026	$60.13M	–
Q4 FY2025CQ2 2025	Jun 30, 2025	$86.48M	–
Q4 FY2024CQ2 2024	Jun 30, 2024	$72.04M	–

Parsed from the XBRL in Radiopharm Theranostics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is RADX.

Revenue growth-23.8% · median 33.9%

Operating margin-2051.5% · median -353.2%

Advertisement
300 × 250

See a number that looks wrong?